Boothbay Fund Management’s Relmada Therapeutics RLMD Stock Holding History

Boothbay Fund Management’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.91M	Sell	564,759 -164,296	-23%	-$1.15M	0.05%	427
2026 Q1	$5.07M	Sell	729,055 -106,245	-13%	-$503K	0.07%	315
2025 Q4	$4.03M	Buy	835,300 +142,064	+20%	+$476K	0.06%	354
2025 Q3	$1.39M	Buy	+693,236	New	+$665K	0.02%	698
2023 Q3	–	Sell	-12,792	Closed	-$31.5K	–	2020
2023 Q2	$31.5K	Hold	12,792	–	–	﹤0.01%	1698
2023 Q1	$28.9K	Hold	12,792	–	–	﹤0.01%	2047
2022 Q4	$44.6K	Buy	+12,792	New	+$112K	﹤0.01%	1882
2021 Q3	–	Sell	-34,353	Closed	-$1.1M	–	2143
2021 Q2	$1.1M	Buy	34,353 +1,142	+3%	+$39.7K	0.04%	644
2021 Q1	$1.17M	Buy	+33,211	New	+$1.16M	0.04%	519

Other funds holding RLMD

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boothbay Fund Management's RLMD Position: Q2 2026 in Review

Boothbay Fund Management reduced its Relmada Therapeutics (RLMD) stake by 23% in Q2 2026, selling an estimated $1.15M and leaving 564,759 shares worth $3.91M. The position accounts for 0.05% of the portfolio, ranked #427.

Boothbay Fund Management first reported a position in RLMD in Q1 2021 and has held it in 9 quarters since. The position peaked at $5.07M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

Boothbay Fund Management held 564,759 shares of Relmada Therapeutics worth $3.91M as of Q2 2026.
Boothbay Fund Management sold 164,296 Relmada Therapeutics shares in Q2 2026, an estimated $1.15M.
Relmada Therapeutics made up 0.05% of Boothbay Fund Management's portfolio in Q2 2026, its #427 holding.
Boothbay Fund Management first reported a position in Relmada Therapeutics in Q1 2021 and has held it in 9 quarters since.
Boothbay Fund Management's Relmada Therapeutics position peaked at $5.07M in Q1 2026.
126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.